Bank of New York Mellon’s Hepion Pharmaceuticals HEPA Stock Holding History

Bank of New York Mellon’s Portfolio HEPA Stock Details HEPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-89	Closed	-$68.9K	–	4423
2023 Q1	$68.9K	Hold	89	–	–	﹤0.01%	4133
2022 Q4	$26.6K	Sell	89 -69	-44%	-$29.2K	﹤0.01%	4320
2022 Q3	$80K	Hold	158	–	–	﹤0.01%	4239
2022 Q2	$91K	Hold	158	–	–	﹤0.01%	4239
2022 Q1	$204K	Hold	158	–	–	﹤0.01%	4229
2021 Q4	$181K	Buy	158 +69	+78%	+$94.5K	﹤0.01%	4305
2021 Q3	$136K	Buy	89 +45	+102%	+$72K	﹤0.01%	4273
2021 Q2	$87K	Sell	44 -5	-10%	-$9.15K	﹤0.01%	4243
2021 Q1	$89K	Buy	49 +8	+20%	+$17.5K	﹤0.01%	4179
2020 Q4	$90K	Buy	+41	New	+$106K	﹤0.01%	4087
2018 Q2	–	Hold	0	–	-$9K	–	4251
2018 Q1	–	Hold	0	–	–	–	4292
2017 Q4	–	Hold	0	–	–	–	4319
2017 Q3	–	Hold	0	–	–	–	4210
2017 Q2	–	Hold	0	–	–	–	4230
2017 Q1	–	Hold	0	–	–	–	4166
2016 Q4	–	Hold	0	–	–	–	4195
2016 Q3	–	Hold	0	–	–	–	4200
2016 Q2	–	Hold	0	–	–	–	4242
2016 Q1	–	Hold	0	–	–	–	4127
2015 Q4	–	Hold	0	–	–	–	4207
2015 Q3	–	Hold	0	–	–	–	4231

Other funds holding HEPA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of New York Mellon's HEPA Position: Q2 2023 in Review

Bank of New York Mellon sold out of Hepion Pharmaceuticals (HEPA) in Q2 2023, closing a stake of 89 shares — an estimated $68.9K sold.

Bank of New York Mellon first reported a position in HEPA in Q4 2020 and held it in 10 quarters. The position peaked at $204K in Q1 2022. 16 funds tracked by Wall St. Rank hold HEPA as of Q2 2023.

Bank of New York Mellon reported no remaining Hepion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Bank of New York Mellon sold 89 Hepion Pharmaceuticals shares in Q2 2023, an estimated $68.9K.
Bank of New York Mellon first reported a position in Hepion Pharmaceuticals in Q4 2020 and held it in 10 quarters.
Bank of New York Mellon's Hepion Pharmaceuticals position peaked at $204K in Q1 2022.
16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.